Rituximab biosimilar - Sunshine Guojian Pharmaceutical

Drug Profile

Rituximab biosimilar - Sunshine Guojian Pharmaceutical

Alternative Names: CMAB304; Retuxira

Latest Information Update: 04 Dec 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Shanghai CP Guojian Pharmaceutical
  • Developer Sunshine Guojian Pharmaceutical
  • Class Antineoplastics; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action CD20 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Diffuse large B cell lymphoma

Most Recent Events

  • 20 Aug 2015 CMAB 304 is still in phase III development for Diffuse large B cell lymphoma in China (IV), company website mentions drug as soon to be launched product
  • 15 Jul 2013 Biomarkers information updated
  • 30 Sep 2006 Phase-III clinical trials in Diffuse large B cell lymphoma in China (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top